These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 1373255

  • 21. [Drug therapy with disodium clodronate combined with radiotherapy of bone metastasis of solid tumors].
    Botturi M, Zanni D, Tosi G.
    Radiol Med; 1990 Nov; 80(5):726-33. PubMed ID: 2148401
    [Abstract] [Full Text] [Related]

  • 22. Palliative treatment of bone metastases in hormone-refractory prostate cancer: effects of pamidronate on the carboxyterminal telopeptide of type-I collagen level in patients with increasing prostate-specific antigen levels.
    Kawashima H, Tanaka T, Kuratsukuri K, Uchida J, Sugimura K, Tamada S, Nishisaka N, Kumata K, Iwai Y, Ikemoto S, Ezaki K, Nakatani T.
    Urol Int; 2007 Nov; 78(4):345-50. PubMed ID: 17495494
    [Abstract] [Full Text] [Related]

  • 23. Combination of somatostatin analog, dexamethasone, and standard androgen ablation therapy in stage D3 prostate cancer patients with bone metastases.
    Koutsilieris M, Mitsiades CS, Bogdanos J, Dimopoulos T, Karamanolakis D, Milathianakis C, Tsintavis A.
    Clin Cancer Res; 2004 Jul 01; 10(13):4398-405. PubMed ID: 15240528
    [Abstract] [Full Text] [Related]

  • 24. Clodronate therapy of metastatic bone disease in patients with prostatic carcinoma.
    Adami S, Mian M.
    Recent Results Cancer Res; 1989 Jul 01; 116():67-72. PubMed ID: 2527401
    [Abstract] [Full Text] [Related]

  • 25. [186Re]HEDP in the palliation of painful bone metastases from cancers other than prostate and breast.
    Minutoli F, Herberg A, Spadaro P, Restifo Pecorella G, Baldari S, Aricò D, Altavilla G, Baldari S.
    Q J Nucl Med Mol Imaging; 2006 Dec 01; 50(4):355-62. PubMed ID: 17043634
    [Abstract] [Full Text] [Related]

  • 26. Prospective randomized Phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma.
    Heidenreich A, Sommer F, Ohlmann CH, Schrader AJ, Olbert P, Goecke J, Engelmann UH.
    Cancer; 2004 Sep 01; 101(5):948-56. PubMed ID: 15329902
    [Abstract] [Full Text] [Related]

  • 27. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
    James ND, Caty A, Borre M, Zonnenberg BA, Beuzeboc P, Morris T, Phung D, Dawson NA.
    Eur Urol; 2009 May 01; 55(5):1112-23. PubMed ID: 19042080
    [Abstract] [Full Text] [Related]

  • 28. [The effects of clodronate for the pain treatment of bone metastasis due to prostate cancer].
    Ozyuvaci E, Altan A, Demir C.
    Agri; 2005 Jan 01; 17(1):49-53. PubMed ID: 15791501
    [Abstract] [Full Text] [Related]

  • 29. Prostate cancer and bone metastases. The effect of clodronate.
    Kylmälä T.
    Ann Chir Gynaecol; 1998 Jan 01; 87(1):59-60. PubMed ID: 9598233
    [No Abstract] [Full Text] [Related]

  • 30. Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study.
    Bracarda S, Tonato M, Rosi P, De Angelis V, Mearini E, Cesaroni S, Fornetti P, Porena M.
    Cancer; 2000 Mar 15; 88(6):1438-44. PubMed ID: 10717628
    [Abstract] [Full Text] [Related]

  • 31. Bisphosphonates in prostate carcinoma.
    Adami S.
    Cancer; 1997 Oct 15; 80(8 Suppl):1674-9. PubMed ID: 9362435
    [Abstract] [Full Text] [Related]

  • 32. Combined therapy of Sr-89 and zoledronic acid in patients with painful bone metastases.
    Storto G, Klain M, Paone G, Liuzzi R, Molino L, Marinelli A, Soricelli A, Pace L, Salvatore M.
    Bone; 2006 Jul 15; 39(1):35-41. PubMed ID: 16434248
    [Abstract] [Full Text] [Related]

  • 33. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer.
    Small EJ, Smith MR, Seaman JJ, Petrone S, Kowalski MO.
    J Clin Oncol; 2003 Dec 01; 21(23):4277-84. PubMed ID: 14581438
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effect of oral clodronate on bone pain. A controlled study in patients with metastic prostatic cancer.
    Elomaa I, Kylmälä T, Tammela T, Viitanen J, Ottelin J, Ruutu M, Jauhiainen K, Ala-Opas M, Roos L, Seppänen J.
    Int Urol Nephrol; 1992 Dec 01; 24(2):159-66. PubMed ID: 1385586
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Clodronate: the potential for the future.
    Powles T.
    Bone; 1991 Dec 01; 12 Suppl 1():S43-4. PubMed ID: 1720014
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.